New drug targets breast cancer in the brain
NCT ID NCT07177950
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain or the lining of the brain and spinal cord. The drug is given either through a vein or directly into the spinal fluid. The goal is to see if it is safe and can shrink or control the brain tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SHR-A1811 (a drug given intravenously or into the spinal fluid)
- What this could lead to
- If successful, this could offer a new treatment option for people with HER2-positive breast cancer that has spread to the brain or spinal lining.
- What could go wrong
- This is an early-phase trial with only 51 participants, so results may not apply broadly. The drug may cause serious side effects, especially neurological toxicity.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?